VX-EC-2-02: A Phase 2, Single Arm, Two Period Study of Sodium Cridanimod in Conjunction with Progestin Therapy in Patients with Endometrial Carcinoma

Protocol: 
AAAR4636
Phase: 
II

VX-EC-2-02: A Phase 2, Single Arm, Two Period Study of Sodium Cridanimod in Conjunction with Progestin Therapy in Patients with Endometrial Carcinoma

Are you Eligible? (Inclusion Criteria)

1. Histologically confirmed papillary serous adenocarcinoma or endometrioid type
of
endometrial carcinoma.
2. Recurrent or persistent progressive disease which is refractory to curative
therapy or
established treatments and cannot be treated with surgery or radiotherapy
3. At least one “target lesion” to be used to assess response or measurable
disease
4. Availability of archived tumor tissue sample

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States